The success of somatic gene therapy is largely dependent on the development of gene transfer vehicles that can safely and efficiently deliver their genetic payload to target cells. It is of equal importance that investigators interested in evaluating new and established gene transfer techniques have at their disposal both properly equipped facilities and the guidance of scientists trained in gene therapy research. The vector core facility was born out of this understanding and is committed to meet the challenges presented by somatic gene transfer. While the primary goal of the core facility is to provide investigators with the methods and materials necessary to establish viral-directed gene therapy protocols for inherited disorders, a significant effort is reserved for research and development. This latter component will primarily focus on establishing AAV as a tool for somatic gene transfer. Housed within the Wistar Institute, the core facility occupies 1250 sq ft of independent laboratory space with direct ties to the main IHGT laboratory. The central location of the core relative to the University of Pennsylvania campus ensures easy access by investigators from various disciplines and academic Departments. Specific services are listed below: (1) Provide-expert consultation and guidance to interested investigators on the use of recombinant viruses for targeted transgene delivery; (2) Instruct the investigator on the theoretical and technical aspects of vector construction, virus production and functional analysis; (3) Assemble, organized, and make available libraries of vectors and recombinant viruses with relevant supporting information; (4) Provide investigators participating in the center access to BL2+ facilities for experiments involving recombinant viruses; (5) Perform simple repetitive analyses such as plaque assays for adenoviruses or helper virus assays for retroviruses and adenoviruses; (6) When appropriate provide a comprehensive service for vector/virus production, including vector construction, virus production, and functional analyses. The Vector Core will provide facilities for use by investigators in Projects I, II, and Ill. The actual services provided by the core will be analyses of viral stocks and biological fluids for total recombinant virus. The core will also perform helper virus assays on retroviral stocks.

Project Start
1998-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Raper, Steven E; Chirmule, Narendra; Lee, Frank S et al. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148-58
Raper, Steven E; Yudkoff, Marc; Chirmule, Narendra et al. (2002) A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 13:163-75
Ye, X; Zimmer, K P; Brown, R et al. (2001) Differences in the human and mouse amino-terminal leader peptides of ornithine transcarbamylase affect mitochondrial import and efficacy of adenoviral vectors. Hum Gene Ther 12:1035-46
Chen, S J; Tazelaar, J; Wilson, J M (2001) Selective repopulation of normal mouse liver by hepatocytes transduced in vivo with recombinant adeno-associated virus. Hum Gene Ther 12:45-50
Chen, S J; Tazelaar, J; Moscioni, A D et al. (2000) In vivo selection of hepatocytes transduced with adeno-associated viral vectors. Mol Ther 1:414-22
Ye, X; Whiteman, B; Jerebtsova, M et al. (2000) Correction of argininosuccinate synthetase (AS) deficiency in a murine model of citrullinemia with recombinant adenovirus carrying human AS cDNA. Gene Ther 7:1777-82
Xiao, W; Chirmule, N; Schnell, M A et al. (2000) Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 1:323-9
Ye, X; Robinson, M B; Pabin, C et al. (2000) Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Ther 7:1761-7
Mitchell, M; Jerebtsova, M; Batshaw, M L et al. (2000) Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther 7:1986-92
Chirmule, N; Moscioni, A D; Qian, Y et al. (1999) Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Hum Gene Ther 10:259-69

Showing the most recent 10 out of 19 publications